A Phase 3 interventional study of fluticasone propionate and fluticasone propionate/salmeterol in Asthma, sponsored by GlaxoSmithKline. Completed at 55 sites in 13 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 45th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 35 in phase 3, and was the 29th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 351 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 62nd largest by enrollment of the 238 interventional ones that give a count, is one of 20 that started in 2007, is one of 61 in phase 3, and was the 39th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
Drug: fluticasone propionate/salmeterol
Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
Drug: fluticasone propionate
fluticasone propionate 100mcg HFA
Drug pages: Fluticasone · Salmeterol Xinafoate
fluticasone propionate/salmeterol 100/50mcg HFA
Possible Drug-Related Adverse Events
Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.
Time frame: Treatment period (weeks 1-12) and Post Treatment (≥1 day after last time study drug)
Investigator Evaluations of Electrocardiogram (ECG) Results
ECGs were transmitted to an independent cardiologist who was responsible for providing interpretation of the ECG as either normal or abnormal (based on personal assessment). The investigator was then responsible for determining the clinical significance of the abnormal ECG in the context of the participants' history and clinical presentation. An abnormal, clinically significant ECG included, but was not limited to: prolonged QT interval, ischemic changes, ventricular hypertrophy, intraventricular conduction abnormalities, and clinically significant arrhythmias. PD, premature discontinuation.
Time frame: Baseline and Week 12
Clinically Significant Unfavorable ECGs at Week 12
Post-randomization ECGs categorized by the primary investigator as no change, significant change (favorable), significant change (unfavorable) from the ECG performed at Visit 1 (Baseline) are presented. Significant change (favorable) includes any ECG that improved from baseline, whereas significant change (unfavorable) includes any ECG that worsened from baseline. Clinical significance is determined by the primary investigator.
Time frame: Baseline, Week 12
ECG Measures - Heart Rate
The range of heart rates for this study was between 49-144 beats per minute
Time frame: Baseline and Week 12
ECG Measures - QT Interval
Fridericia's formula QTc interval=QT interval/cubed root of the R-R interval. The Bazett's formula QTc=QT/squared root of the R-R interval.
Time frame: Baseline and Week 12
Cardiovascular Adverse Events Reported During Treatment Period
Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Treatment Period. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event. Please see the category titles for a list of candidate cardiovascular adverse events.
Time frame: 12-Week Treatment Period
Cardiovascular Adverse Events Reported During the Post-Treatment Period
Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Post-treatment period, defined as 1 day after last dose of study drug. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event.
Time frame: 5 Days after Week 12
Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols
The Primary Investigator determined the severity of the exacerbation based on the participant's clinical presentation and the investigator's understanding of the disease, the participant, and his or her clinical experiences. The severity of the exacerbation was not defined in the protocol. Mild: Usually treated at home. Prompt relief with inhaled short-acting beta2 agonist. Possible short course of oral systemic corticosteroids. Moderate: Usually requires office or emergency department visit. Relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for 1-2 days after treatment begins. Severe: Usually requires emergency department visit and likely hospitalization. Partial relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for more than 3 days after treatment begins. Adjunctive therapies are helpful.
Time frame: Treatment period (weeks 1-12)
Number of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion
"Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. The normal range for cortisol levels vary by age and gender. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
Time frame: Baseline and week 12
Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12
Normal range for Cortisol levels vary by age and gender. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
Time frame: Baseline and Week 12
Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion
Normal range for Cortisol levels vary by age and gender. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
Time frame: Baseline and Week 12
Number of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
Time frame: Baseline and Week 12
Geometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
Time frame: Baseline and Week 12
Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
Time frame: Baseline and Week 12
Clinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years
FEV1 (Forced Expiratory Volume in 1 second) is the volume of air that can be forced out in one second, after taking a deep breath. FEV1 is measured using a spirometer and obtaining "best effort" from 3 to 8 measurements. Week 12 is the measure taken at Week 12.
Time frame: Baseline and week 12
AM Peak Expiratory Flow
The peak expiratory flow (PEF) rate measures how fast a person can exhale air. It is used to compare to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43 inches is 147 Liters/minute (L/min), whose height is 66 inches is 454 L/min. Triplicate measurements taken for the best effort recorded.
Time frame: Baseline and 12-Week Treatment Period
Asthma Symptom Scores
Each morning prior dosing or PEF, self-scored based on past 24 hours: 0=No symptoms, 1=Symptoms for one short period, 2=Symptoms for two or more short periods, 3=Frequent Symptoms which did not affect activities of daily living (ADL), 4=Frequent.
Time frame: Baseline and 12-Week Treatment Period
Percentage of Symptom Free Days
Percentage of number of days without asthma symptoms based on Asthma Symptom Scores. Each morning prior to dosing or PEF, asthma symptoms were self-scored based on the past 24 hours: 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=frequent symptoms that did not affect activities of daily living (ADL), 4=frequent .
Time frame: Baseline and 12-Week Treatment Period
Albuterol Use
Albuterol inhalation aerosol was used as a rescue or prophylactic and recorded daily by subject or caregiver. The number of puffs of albuterol over the previous 24 hour period prior to dosing was recorded.
Time frame: Baseline and 12-Week Treatment Period
Percent of Albuterol-free Days
Percentage of days when Albuterol use was unnecessary based on daily record and symptom free days.
Time frame: Baseline and 12-Week Treatment Period
A total of 351 participants were enrolled in the study. However, only 350 of these 351 participants comprised the Intent-to-Treat Population, defined as all participants who were randomly assigned to treatment and received \>=1 dose of Double-Blind study treatment.
| Milestone | Fluticasone Propionate/Salmeterol Hydrofluoroalkane (HFA) | Fluticasone Propionate HFA |
|---|---|---|
| Started | 173 | 177 |
| Completed | 162 | 163 |
| Not completed | 11 | 14 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Protocol violation | 4 | 6 |
| Withdrew: Exacerbation of asthma | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Other | 3 | 3 |
Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Participants with any drug-related event | 13 | 16 |
| Investigations - ECG QTc interval prolonged | 9 | 4 |
| Investigations - QT interval prolonged | 0 | 2 |
| Investigations - ECG QT borderline prolonged | 1 | 0 |
| Investigations - ECG QT interval abnormal | 1 | 0 |
| Cardiac - Defect conduction intraventricular | 2 | 7 |
| Cardiac - Conduction disorder | 1 | 1 |
| Cardiac - Sinus tachycardia | 1 | 0 |
| Cardiac - Supraventricular ectopics | 0 | 1 |
| Infections/Infestations - Oral candidiasis | 0 | 1 |
| Infections/Infest - Oropharyngeal candidiasis | 0 | 1 |
| Respiratory/thoracic/mediastinal - Dysphonia | 2 | 0 |
ECGs were transmitted to an independent cardiologist who was responsible for providing interpretation of the ECG as either normal or abnormal (based on personal assessment). The investigator was then responsible for determining the clinical significance of the abnormal ECG in the context of the participants' history and clinical presentation. An abnormal, clinically significant ECG included, but was not limited to: prolonged QT interval, ischemic changes, ventricular hypertrophy, intraventricular conduction abnormalities, and clinically significant arrhythmias. PD, premature discontinuation.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Normal | 145 | 155 |
| Baseline - Abnormal: Not Clinically Significant | 27 | 21 |
| Baseline - Abnormal: Clinically Significant | 1 | 0 |
| Week 12-No Change or insignificant Change | 136 | 142 |
| Week 12-Clinically Significant Change-Favorable | 2 | 0 |
| Week 12-Clinically Significant Change-Unfavorable | 24 | 18 |
| PD-No Change or insignificant Change | 7 | 9 |
| PD-Clinically Significant Change-Favorable | 0 | 1 |
| PD-Clinically Significant Change-Unfavorable | 0 | 1 |
Post-randomization ECGs categorized by the primary investigator as no change, significant change (favorable), significant change (unfavorable) from the ECG performed at Visit 1 (Baseline) are presented. Significant change (favorable) includes any ECG that improved from baseline, whereas significant change (unfavorable) includes any ECG that worsened from baseline. Clinical significance is determined by the primary investigator.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Clinically significant unfavorable change | 24 | 18 |
| AEs Reported for ECG findings | 22 | 18 |
| Clinically significant unfavorable ECGs repeated | 11 | 11 |
| Repeated ECGs w/ no change or insignificant change | 6 | 5 |
The range of heart rates for this study was between 49-144 beats per minute
| beats per minute | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Mean Heart Rate - Baseline | 84 (53 to 144) | 82.6 (51 to 136) |
| Mean Heart Rate - Week 12 | 85.5 (59 to 138) | 81.9 (52 to 121) |
| Mean Heart Rate - Premature Discontinuation | 73.1 (53 to 90) | 92.4 (49 to 130) |
Fridericia's formula QTc interval=QT interval/cubed root of the R-R interval. The Bazett's formula QTc=QT/squared root of the R-R interval.
| milliseconds | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Mean QTc Interval (Fridericia)- Baseline | 394.5 (340 to 449) | 390.8 (338 to 429) |
| Mean QTc Interval (Fridericia) - Week 12 | 397.5 (355 to 439) | 393.6 (329 to 449) |
| Premature Discontinuation (Fridericia) | 392 (359 to 417) | 394.8 (376 to 408) |
| Mean QTc Interval (Bazett) - Baseline | 416.3 (356 to 464) | 411.4 (346 to 471) |
| Mean QTc Interval (Bazett) - Week 12 | 420.8 (368 to 466) | 413.7 (351 to 477) |
| Premature Discontinuation (Bazett) | 403.3 (376 to 446) | 422.7 (378 to 454) |
Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Treatment Period. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event. Please see the category titles for a list of candidate cardiovascular adverse events.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Participants with Any Event | 98 | 103 |
| Electrocardiogram (ECG) Change | 3 | 2 |
| ECG QTc Interval Prolonged | 2 | 1 |
| ECG Abnormal | 1 | 1 |
| ECG QT Borderline Prolonged | 1 | 0 |
| Defect Conduction Intraventricular | 4 | 3 |
| Cardiac Arrhythmia | 1 | 0 |
| Premature Atrial Contraction | 1 | 0 |
Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Post-treatment period, defined as 1 day after last dose of study drug. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Participants with Any Event | 19 | 19 |
| ECG QTc interval prolonged | 11 | 5 |
| QT interval prolonged | 1 | 2 |
| ECG QT interval Abnormal | 1 | 0 |
| Defect Conduction Intraventricular | 2 | 7 |
| Conduction disorder | 1 | 1 |
| Sinus Tachycardia | 1 | 0 |
| Supraventricular Ectopics | 0 | 1 |
The Primary Investigator determined the severity of the exacerbation based on the participant's clinical presentation and the investigator's understanding of the disease, the participant, and his or her clinical experiences. The severity of the exacerbation was not defined in the protocol. Mild: Usually treated at home. Prompt relief with inhaled short-acting beta2 agonist. Possible short course of oral systemic corticosteroids. Moderate: Usually requires office or emergency department visit. Relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for 1-2 days after treatment begins. Severe: Usually requires emergency department visit and likely hospitalization. Partial relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for more than 3 days after treatment begins. Adjunctive therapies are helpful.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Participants with any asthma exacerbation | 1 | 3 |
| Severity - Mild | 1 | 2 |
| Severity - Moderate/Severe | 0 | 1 |
| Withdrawal due to Asthma Exacerbation | 1 | 2 |
"Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. The normal range for cortisol levels vary by age and gender. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
| participants | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Abnormal high cortisol excretion, n | 13 | 17 |
| Baseline - Abnormal low cortisol excretion, n | 1 | 0 |
| Week 12 - Abnormal high cortisol excretion, n | 13 | 8 |
| Week 12 - Abnormal low cortisol excretion, n | 2 | 0 |
Normal range for Cortisol levels vary by age and gender. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
| Nanomoles per 24 hours (nmol/24 hrs) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Geometric Mean | 32.71 (2.7 to 156.2) | 30.88 (4.2 to 891.6) |
| Week 12 - Geometric Mean | 25.03 (1.7 to 152.6) | 23.17 (5.3 to 145.8) |
Normal range for Cortisol levels vary by age and gender. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
| ratio | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion | 0.77 | 0.75 |
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.
| participants | Fluticasone Propionate/Salmeterol HFA - Spacer | Fluticasone Propionate/Salmeterol HFA - No Spacer | Fluticasone Propionate HFA - Spacer | Fluticasone Propionate HFA - No Spacer |
|---|---|---|---|---|
| Baseline - Abnormal high cortisol excretion | 12 | 1 | 14 | 3 |
| Baseline - Abnormal low cortisol excretion | 0 | 1 | 0 | 0 |
| Week 12 - Abnormal high cortisol excretion | 10 | 3 | 7 | 1 |
| Week 12 - Abnormal low cortisol excretion | 2 | 0 | 0 | 0 |
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
| Nanomoles per 24 hours (nmol/24 hrs) | Fluticasone Propionate/Salmeterol HFA - Spacer | Fluticasone Propionate/Salmeterol HFA - No Spacer | Fluticasone Propionate HFA - Spacer | Fluticasone Propionate HFA - No Spacer |
|---|---|---|---|---|
| Baseline - Geometric Mean | 31.89 (3.6 to 156.2) | 35.84 (2.7 to 143.3) | 30.61 (4.2 to 891.6) | 31.89 (7.9 to 335.0) |
| Week 12 - Geometric Mean | 23.37 (1.7 to 143.3) | 32.05 (4.6 to 152.6) | 23.20 (5.3 to 103.2) | 23.06 (5.4 to 145.8) |
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).
| ratio | Fluticasone Propionate/Salmeterol HFA - Spacer | Fluticasone Propionate/Salmeterol HFA - No Spacer | Fluticasone Propionate HFA - Spacer | Fluticasone Propionate HFA - No Spacer |
|---|---|---|---|---|
| Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use | 0.73 | 0.89 | 0.76 | 0.72 |
FEV1 (Forced Expiratory Volume in 1 second) is the volume of air that can be forced out in one second, after taking a deep breath. FEV1 is measured using a spirometer and obtaining "best effort" from 3 to 8 measurements. Week 12 is the measure taken at Week 12.
| Liters per second (L/sec) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean FEV1 | 1.67 ± 0.035 | 1.64 ± 0.035 |
| Week 12 - Mean FEV1 | 1.91 ± 0.038 | 1.82 ± 0.036 |
| Week 12 - Mean Change from baseline | 0.24 ± 0.023 | 0.18 ± 0.023 |
| Premature discontinuation - Mean FEV1 | 1.81 ± 0.14 | 1.70 ± 0.212 |
| Premature discontin. - Mean Change from baseline | 0.03 ± 0.09 | -0.07 ± 0.120 |
The peak expiratory flow (PEF) rate measures how fast a person can exhale air. It is used to compare to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43 inches is 147 Liters/minute (L/min), whose height is 66 inches is 454 L/min. Triplicate measurements taken for the best effort recorded.
| Liters/minute (L/min) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean AM PEF | 213 ± 4.83 | 203 ± 4.37 |
| Weeks 1-12 - Mean AM PEF | 233 ± 5.07 | 220 ± 4.43 |
| Weeks 1-12 - Mean Change from Baseline | 20.2 ± 2.04 | 17.4 ± 1.86 |
| Last 7 Days on Treatment - Mean AM PEF | 238 ± 5.39 | 226 ± 4.73 |
| Last 7 Days on Treatment-Mean Change from Baseline | 25.3 ± 2.58 | 23.3 ± 2.47 |
Each morning prior dosing or PEF, self-scored based on past 24 hours: 0=No symptoms, 1=Symptoms for one short period, 2=Symptoms for two or more short periods, 3=Frequent Symptoms which did not affect activities of daily living (ADL), 4=Frequent.
| Score in scale | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean Score | 1.3 ± 0.06 | 1.4 ± 0.06 |
| Weeks 1-12 - Mean Score | 0.9 ± 0.06 | 0.8 ± 0.05 |
| Weeks 1-12 - Mean change from baseline | -0.4 ± 0.06 | -0.6 ± 0.06 |
| Last 7 Days on Treatment - Mean Score | 0.8 ± 0.07 | 0.8 ± 0.07 |
| Last 7 Days on Treat. - Mean change from baseline | -0.5 ± 0.07 | -0.6 ± 0.08 |
Percentage of number of days without asthma symptoms based on Asthma Symptom Scores. Each morning prior to dosing or PEF, asthma symptoms were self-scored based on the past 24 hours: 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=frequent symptoms that did not affect activities of daily living (ADL), 4=frequent .
| Percentage of days | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean Percent | 20.0 ± 2.02 | 18.4 ± 2.00 |
| Weeks 1-12 - Mean Percent | 46.7 ± 2.77 | 48.7 ± 2.80 |
| Weeks 1-12 - Mean change from baseline | 26.8 ± 2.47 | 30.5 ± 2.62 |
| Last 7 Days on Treatment - Mean Percent | 51.9 ± 3.51 | 53.4 ± 3.44 |
| Last 7 Days on Treat. - Mean change from baseline | 32.1 ± 3.32 | 34.9 ± 3.43 |
Albuterol inhalation aerosol was used as a rescue or prophylactic and recorded daily by subject or caregiver. The number of puffs of albuterol over the previous 24 hour period prior to dosing was recorded.
| Number of puffs per 24 hours | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean number of puffs | 1.5 ± 0.12 | 1.8 ± 0.19 |
| Weeks 1-12 - Mean number of puffs | 1.0 ± 0.09 | 0.9 ± 0.09 |
| Weeks 1-12 - Mean change from baseline | -0.6 ± 0.12 | -1.0 ± 0.16 |
| Last 7 Days on Treatment - Mean number of puffs | 0.7 ± 0.11 | 0.7 ± 0.11 |
| Last 7 Days on Treat. - Mean change from baseline | 0.15 ± 0.8 | -1.2 ± 0.19 |
Percentage of days when Albuterol use was unnecessary based on daily record and symptom free days.
| Percentage of days | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Mean percent rescue free | 43.7 ± 2.85 | 42.5 ± 3.04 |
| Weeks 1-12 - Mean percent rescue free | 67.1 ± 2.46 | 70.0 ± 2.40 |
| Weeks 1-12 - Mean change from baseline | 23.6 ± 2.79 | 28.3 ± 2.93 |
| Last 7 Days on Treat. - Mean percent rescue free | 75.4 ± 2.96 | 75.8 ± 2.98 |
| Last 7 Days on Treat. - Mean change from baseline | 30.4 ± 3.50 | 32.8 ± 3.58 |
A post-hoc analysis excluding participants with urine cortisol baseline values of \>200 nanomoles/24 hours. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
| Nanamoles per 24 hours (nmol/24 hrs) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Baseline - Geometric Mean | 32.71 (2.7 to 156.2) | 28.39 (4.2 to 146.9) |
| Week 12 - Geometric Mean | 25.03 (1.7 to 152.6) | 22.80 (5.3 to 145.8) |
A post-hoc analysis excluding participants with urine cortisol baseline values of \>200 nmol/24 hrs. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs) .
| ratio | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Geometric Mean Ratio for Baseline:Week12 24-hour Urinary Cortisol Excretion | 0.77 | 0.80 |
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.
| Nanomoles per 24 hr (nmoles/24 hr) | No Spacer | Spacer |
|---|---|---|
| Baseline - Geometric Mean | 31.88 (7.9 to 81.7) | 27.08 (3.6 to 166.3) |
| Week 12 - Geometric Mean | 27.85 (5.4 to 152.6) | 22.38 (1.7 to 143.3) |
AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value,nanomoles per 24 hours (nmol/24 hrs) .
| ratio | Spacer | No Spacer |
|---|---|---|
| Geometric Mean Ratio for Baseline: Week 12 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population | 0.87 | 0.83 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Propionate/Salmeterol HFA | — | 1/173 (0.6%) | 61/173 (35.3%) |
| Fluticasone Propionate HFA | — | 0/177 (0%) | 68/177 (38.4%) |
| Event | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| Head Injury due to fallInjury, poisoning and procedural complications | 1/173 | 0/177 |
| Event | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA |
|---|---|---|
| HeadacheNervous system disorders | 26/173 | 25/177 |
| NasopharyngitisInfections and infestations | 16/173 | 21/177 |
| PyrexiaGeneral disorders | 8/173 | 16/177 |
| Upper Respiratory Tract InfectionInfections and infestations | 11/173 | 13/177 |
| PharyngitisInfections and infestations | 4/173 | 12/177 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/173 | 7/177 |
| RhinitisInfections and infestations | 8/173 | 6/177 |
| Age, Customized(participants) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA | Total |
|---|---|---|---|
| 4-5 years | 36 | 41 | 77 |
| 6-11 years | 137 | 136 | 273 |
| Gender(Participants) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA | Total |
|---|---|---|---|
| Female | 66 | 71 | 137 |
| Male | 107 | 106 | 213 |
| Ethnicity (NIH/OMB)(Participants) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA | Total |
|---|---|---|---|
| Hispanic or Latino | 70 | 73 | 143 |
| Not Hispanic or Latino | 103 | 104 | 207 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Fluticasone Propionate/Salmeterol HFA | Fluticasone Propionate HFA | Total |
|---|---|---|---|
| White/Caucasian/European Heritage | 114 | 113 | 227 |
| American Indian or Alaska Native | 24 | 27 | 51 |
| Central/South Asian Heritage | 8 | 8 | 16 |
| African American/African Heritage | 7 | 8 | 15 |
| Japanese Heritage | 3 | 0 | 3 |
| Arabic/North African Heritage | 2 | 2 | 4 |
| South East Asian Heritage | 2 | 0 | 2 |
| Mixed Race | 13 | 19 | 32 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate